The Biomedical Diagnostics Institute (BDI) based at Dublin City University (DCU) has announced that it has invested in Biacore A100 label-free protein interaction analysis system.
The BDI is focused on the development of novel point of care diagnostics for detecting, for example, cardiac conditions, cancer, mastitis in cattle, and blood coagulation monitoring.
Biacore A100 was officially launched by the BDI on 7 October 2008.
The investment in the instrument was made possible following a significant award from Science Foundation Ireland (SFI).
The BDI becomes the first academic research institute in Europe to own Biacore A100.
Biacore A100 was thoroughly evaluated by BDI scientists prior to being installed at DCU.
The high quality and high content data generated by the instrument, parallel sample analysis and high productivity, along with the ability to analyse 2,000 interactions in 24 hours were key factors in the decision to purchase the instrument.
In addition, the biosensor utilises sensor chips amenable to a variety of immobilisation chemistries, enabling it to be used for a wide range of applications.
